A proxy fight over the election of a director looms at Echo Therapeutics' (ECTE +2.4%) June 19 shareholders meeting. The company favors current director and interim CEO Robert F. Doman while institutional shareholder Platinum Management favors Shepard M. Goldberg. As is usually the case, the core of the dispute pertains to the strategic direction of the company.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs